Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Nov 4, 2024, 4:00 PM
1.070
+0.040 (3.88%)
After-hours: Nov 4, 2024, 5:34 PM EST
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CLSD stock have an average target of 5.17, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 401.94% from the current stock price of 1.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLSD stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +482.52% | Oct 14, 2024 |
| Needham | Needham | Strong Buy Maintains $4 → $6 | Strong Buy | Maintains | $4 → $6 | +482.52% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +385.44% | Aug 27, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +482.52% | Aug 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +385.44% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
565.38K
from 8.23M
Decreased by -93.13%
Revenue Next Year
3.05M
from 565.38K
Increased by 438.58%
EPS This Year
-0.50
from -0.53
EPS Next Year
-0.51
from -0.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.1M | 16.9M | 34.3M | ||
| Avg | 565,376 | 3.0M | 13.5M | ||
| Low | 294,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -87.2% | 2,896.8% | 1,025.9% | ||
| Avg | -93.1% | 438.6% | 344.5% | ||
| Low | -96.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.45 | -0.38 | -0.35 | ||
| Avg | -0.50 | -0.51 | -0.61 | ||
| Low | -0.58 | -0.64 | -1.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.